Results 111 to 120 of about 5,926 (192)

Advances in PARP Inhibition in Improving Outcomes of Breast Cancer, Ovarian Cancer, and Other Solid Tumors: Journey of Discovery, Development, and Clinical Updates of Talazoparib. [PDF]

Drug Des Devel Ther
Latif M, Mazhar S, Tasleem M, Alqurashi A, Arfan M, Ashraf Z, Zafar MS.   +6 more
europepmc   +1 more source

Limitations of Subgroup Safety Analyses for Drug-Drug Interaction Evaluation: Insights from the Talazoparib P-gp Inhibitor Case. [PDF]

J Clin Pharmacol
Wang D, Nanavati C, Yang DZ, DeAnnuntis L, Elmeliegy M.   +4 more
europepmc   +1 more source

Nucleophagy removes cytotoxic trapped PARP1. [PDF]

Nat Cell Biol
Hoslett G, Tribble S, Lascaux P, Koukouravas S, Torrecilla I, Song W, Hou CX, Li J, González-Fernández M, De Gregoriis G, Dagg RA, O'Brien D, Pierangelini A, Martial T, Ng AWT, Raimundo N, Milosevic I, Freire R, Li Y, Rottenberg S, Krastev DB, Lord CJ, Tarsounas M, Ramadan K.   +23 more
europepmc   +1 more source

Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion. [PDF]

Proc Natl Acad Sci U S A
Abdulkareem NM, Jiang Y, Qi Y, Liu X, Zhang X, Cai S, Shao J, Jeter-Jones S, Rinkenbaugh AL, Cheng CC, Hancock F, Schwartz J, Litton JK, Chang JT, Piwnica-Worms H.   +14 more
europepmc   +1 more source

MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer. [PDF]

Cancer Res
Gulla S, Sharma T, Gardner E, Li C, Purohit TA, Xue C, Colligan S, Shyam Sundar S, Yang B, Trostel SY, Capaldo B, Bard JE, Ogunbowale T, Jawadwala A, Ma M, Qu J, Karzai F, Pili R, Jarrard DF, Sowalsky AG, VanderWeele DJ, Adelaiye-Ogala R.   +21 more
europepmc   +1 more source

SLFN11 expression as a marker of small cell lung cancer vulnerability to combined PARP inhibitors and immune checkpoint inhibitors during maintenance. [PDF]

J Thorac Dis
Pujol JL.
europepmc   +1 more source

Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer. [PDF]

Biomedicines
Correa Gonzalez B, Karthikeyan A, Moore LA, Bhaumik A, Sandoval E, Hardy M, McPherson JD, Li H, Parikh M, Dall'Era M, Gao AC, Lombard AP.   +11 more
europepmc   +1 more source

Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors. [PDF]

RSC Adv
Rani D, Plebanski M, Chatterjee T.
europepmc   +1 more source

Biomarker-driven maintenance therapy in extensive-stage-small cell lung cancer: evaluating the SWOG S1929 clinical trial. [PDF]

J Thorac Dis
Johnston T, Breadner D, Raphael J.
europepmc   +1 more source

Talazoparib (Talzenna™)

Oncology Times, 2019
openaire   +2 more sources